Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Finerenone

FDA-approved product (tablet, oral), marketed as Kerendia.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Finerenone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Chronic kidney disease
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Aldosterone antagonists
FDA pharmacologic class
Nonsteroidal Mineralocorticoid-Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis45.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Finerenone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Finerenone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide

    NCT07819227 · start 2025-02-11

    Registered record
    Registry ID
    NCT07819227
    Conditions
    Chronic Kidney Disease
    Interventions
    Finerenone (BAY 94-8862); Semaglutide 14 MG [Rybelsus]; Finerenone and Semaglutide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2025-02-11
    Completion
    2026-08-31
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease
    InterventionFinerenone (BAY 94-8862); Semaglutide 14 MG [Rybelsus]; Finerenone and Semaglutide
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT

    NCT06818305 · start 2025-01-01

    Registered record
    Registry ID
    NCT06818305
    Conditions
    Renal Cell Carcinoma (Kidney Cancer); Renal Cell Carcinoma (RCC); Nephrectomy; Chronic Kidney Disease(CKD)
    Interventions
    Finerenone (BAY 94-8862); Empagliflozin 10 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2025-01-01
    Completion
    2025-10-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Carcinoma (Kidney Cancer); Renal Cell Carcinoma (RCC); Nephrectomy; Chronic Kidney Disease(CKD)
    InterventionFinerenone (BAY 94-8862); Empagliflozin 10 mg
    PhasePhase 2
    Registry statusTerminated

  • Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease

    NCT06727409 · start 2024-12-12

    Registered record
    Registry ID
    NCT06727409
    Conditions
    Patients With Type 2 Diabetes
    Interventions
    Finerenone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-12-12
    Completion
    2026-12-31
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients With Type 2 Diabetes
    InterventionFinerenone
    PhasePhase 4
    Registry statusRecruiting

  • Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy

    NCT06573411 · start 2024-09-30

    Registered record
    Registry ID
    NCT06573411
    Conditions
    Primary Membranous Nephropathy
    Interventions
    ACEI/ARB+ finerenone; ACEI/ARB
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-09-30
    Completion
    2026-10-30
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Membranous Nephropathy
    InterventionACEI/ARB+ finerenone; ACEI/ARB
    PhasePhase 4
    Registry statusRecruiting

  • A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

    NCT06033950 · start 2024-08-20

    Registered record
    Registry ID
    NCT06033950
    Conditions
    Heart Failure
    Interventions
    Finerenone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-08-20
    Completion
    2028-01
    Enrolment
    2,600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionFinerenone; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial

    NCT06094920 · start 2024-07-29

    Registered record
    Registry ID
    NCT06094920
    Conditions
    Diabetes Mellitus Type 2 With Proteinuria; Diabetes Mellitus, Type 2; Diabetes Mellitus; Diabetes; Diabetes Complications; Albuminuria; Chronic Kidney Diseases; Chronic Kidney Disease Due to Type 2 Diabetes Mellitus; Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; CKD; CKD Stage 3; CKD Stage 4
    Interventions
    Empagliflozin 10 MG; Finerenone; Withings BPM Connect; Withings Body; PeeSpot Urine Collection Device; Hem-Col Capillary Blood Collection Device; Questionnaire: participants' perspectives toward the feasibility of participation in a trial at home with digital technologies
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-07-29
    Completion
    2025-09-24
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus Type 2 With Proteinuria; Diabetes Mellitus, Type 2; Diabetes Mellitus; Diabetes +9 more
    InterventionEmpagliflozin 10 MG; Finerenone; Withings BPM Connect; Withings Body +3 more
    PhasePhase 4
    Registry statusCompleted

  • A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

    NCT06024746 · start 2024-07-09

    Registered record
    Registry ID
    NCT06024746
    Conditions
    Heart Failure
    Interventions
    Finerenone; Empagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-07-09
    Completion
    2027-11
    Enrolment
    1,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionFinerenone; Empagliflozin
    PhasePhase 3
    Registry statusRecruiting

  • Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

    NCT06082063 · start 2024-07-01

    Registered record
    Registry ID
    NCT06082063
    Conditions
    Cardiovascular Diseases; Heart Failure; Type 1 Diabetes; Kidney Failure
    Interventions
    Aspirin tablet; Semaglutide; Sotagliflozin; Finerenone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-07-01
    Completion
    2029-07-01
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Heart Failure; Type 1 Diabetes; Kidney Failure
    InterventionAspirin tablet; Semaglutide; Sotagliflozin; Finerenone
    PhasePhase 3
    Registry statusRecruiting

  • Influence of Neurohormonal Blockade on Natriuresis in Heart Failure Patients

    NCT07781826 · start 2024-03-01

    Registered record
    Registry ID
    NCT07781826
    Conditions
    Heart Failure
    Interventions
    Neurohormonal blockade intensification
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2024-03-01
    Completion
    2025-12-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionNeurohormonal blockade intensification
    PhaseEarly phase 1
    Registry statusCompleted

  • A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

    NCT05901831 · start 2024-02-26

    Registered record
    Registry ID
    NCT05901831
    Conditions
    Chronic Kidney Disease; Type 1 Diabetes Mellitus
    Interventions
    Finerenone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2024-02-26
    Completion
    2025-09-15
    Enrolment
    241

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease; Type 1 Diabetes Mellitus
    InterventionFinerenone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Finerenone and Renal Oxidative Stress

    NCT06244758 · start 2024-01-18

    Registered record
    Registry ID
    NCT06244758
    Conditions
    Type2diabetes
    Interventions
    Finerenone 20 MG Oral Tablet; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2024-01-18
    Completion
    2025-11-25
    Enrolment
    91

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType2diabetes
    InterventionFinerenone 20 MG Oral Tablet; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism

    NCT06164379 · start 2023-12-16

    Registered record
    Registry ID
    NCT06164379
    Conditions
    Primary Aldosteronism
    Interventions
    Finerenone; Spironolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-12-16
    Completion
    2024-12-16
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Aldosteronism
    InterventionFinerenone; Spironolactone
    PhasePhase 4
    Registry statusUnknown

  • Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)

    NCT05887817 · start 2023-09-07

    Registered record
    Registry ID
    NCT05887817
    Conditions
    Type 2 Diabetes; Chronic Kidney Diseases
    Interventions
    Finerenone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-09-07
    Completion
    2026-07-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes; Chronic Kidney Diseases
    InterventionFinerenone; Placebo
    PhasePhase 4
    Registry statusUnknown

  • Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study

    NCT05897372 · start 2023-08-01

    Registered record
    Registry ID
    NCT05897372
    Conditions
    Diabetic Kidney Disease
    Interventions
    ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2023-08-01
    Completion
    2024-09-23
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Kidney Disease
    InterventionACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib
    PhasePhase 2
    Registry statusTerminated

  • Efficacy and Safety of Finerenone in Heart Failure With Reduced Ejection Fraction

    NCT05974566 · start 2023-08-01

    Registered record
    Registry ID
    NCT05974566
    Conditions
    Heart Failure With Reduced Ejection Fraction; Diabetes Mellitus; Diabetic Nephropathies
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2023-08-01
    Completion
    2023-10-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure With Reduced Ejection Fraction; Diabetes Mellitus; Diabetic Nephropathies
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown